logo
Share SHARE
FONT-SIZE Plus   Neg

Icon Bioscience Names David Tierney President & CEO - Quick Facts

Icon Bioscience Inc., a privately held specialty biopharmaceutical company focused on the development and commercialization of unique ophthalmic pharmaceuticals based on its patented and proprietary Verisome drug delivery technology, said that David Tierney joined the Company as President & Chief Executive Officer.

Previously, Tierney served as President & COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in mid-2008. Oceana quickly established a global commercial network and by December 2011 was acquired by Salix Pharmaceuticals (SLXP).

In 2000, David was appointed President & CEO of Hydro Med Sciences (HMS), a research firm with a promising drug delivery platform. Under his leadership, HMS emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2005. Valera has since been merged into Endo Pharmaceuticals (ENDP). Prior to Valera, Tierney was President of Biovail Technologies, a drug delivery division of Biovail Corporation - a predecessor to Valeant Pharmaceuticals International (VRX). Earlier in his career, he served as Senior VP, Drug Development at Roberts Pharmaceutical and in a variety of management positions at Elan Corporation.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
French real estate company Unibail-Rodamco SE Tuesday announced that it has entered into an agreement to acquire Australian shopping centre group Westfield Corp. in a deal that implies an enterprise value of $24.7 billion. The deal is expected to create the world's premier developer and operator of flagship shopping destinations with 61.1 billion euros or $72.2 billion of Gross Market Value. Aerospace and defense major Boeing's shares increased in the extended trading on Monday after the company announced a 20 percent increase in quarterly dividend and also boosted its share repurchase program to $18 billion, citing its strong and growing cash flow. Checkout the companies that are expected to release quarterly financial results on Tuesday, December 12, 2017. * ARWR to benefit from collaboration agreement with Amgen * Demand for PoS software, PaaS technologies to propel PAY Q4
comments powered by Disqus
Follow RTT